Wave Life Sciences (WVE) Accounts Payables (2014 - 2026)

Wave Life Sciences' Accounts Payables history runs 13 years deep, the most recent figure standing at $19.1 million for Q1 2026.

• Quarterly Accounts Payables rose 32.78% year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.1 million (up 32.78% YoY) and the FY2025 annual result came in at $15.7 million, down 3.46% from the prior year.
• Accounts Payables was $19.1 million for Q1 2026 at Wave Life Sciences, up from $15.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $19.1 million in Q1 2026 and bottomed at $9.9 million in Q1 2022.
• A 5-year average of $14.2 million and a median of $14.4 million in 2025 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 132.32% in 2022, while the deepest fall reached 26.57% in 2022.
• Wave Life Sciences' Accounts Payables stood at $16.9 million in 2022, then retreated by 24.1% to $12.8 million in 2023, then grew by 26.66% to $16.3 million in 2024, then dropped by 3.46% to $15.7 million in 2025, then rose by 21.43% to $19.1 million in 2026.
• Business Quant data shows WVE's Accounts Payables at $19.1 million in Q1 2026, $15.7 million in Q4 2025, and $14.5 million in Q3 2025.